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Endometriosis is a debilitating, estrogen-dependent, progesterone-
resistant, inflammatory gynecological disease of reproductive age
women. Two major clinical symptoms of endometriosis are chronic
intolerable pelvic pain and subfertility or infertility, which pro-
foundly affect the quality of life in women. Current hormonal
therapies to induce a hypoestrogenic state are unsuccessful because
of undesirable side effects, reproductive health concerns, and failure
to prevent recurrence of disease. There is a fundamental need to
identify nonestrogen or nonsteroidal targets for the treatment of
endometriosis. Peritoneal fluid concentrations of prostaglandin E2
(PGE2) are higher in women with endometriosis, and this increased
PGE2 plays important role in survival and growth of endometriosis
lesions. The objective of the present study was to determine the
effects of pharmacological inhibition of PGE2 receptors, EP2 and EP4,
on molecular and cellular aspects of the pathogenesis of endome-
triosis and associated clinical symptoms. Using human fluorescent
endometriotic cell lines and chimeric mouse model as preclinical
testing platform, our results, to our knowledge for the first time,
indicate that selective inhibition of EP2/EP4: (i) decreases growth
and survival of endometriosis lesions; (ii) decreases angiogenesis
and innervation of endometriosis lesions; (iii) suppresses proinflam-
matory state of dorsal root ganglia neurons to decrease pelvic pain;
(iv) decreases proinflammatory, estrogen-dominant, and proges-
terone-resistant molecular environment of the endometrium and
endometriosis lesions; and (v) restores endometrial functional re-
ceptivity throughmultiple mechanisms. Our novel findings provide a
molecular and preclinical basis to formulate long-term nonestrogen
or nonsteroidal therapy for endometriosis.
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Endometriosis is a debilitating, chronic inflammatory gyneco-logical disease of reproductive age women. Two major clinical
symptoms of endometriosis are chronic intolerable pelvic pain and
subfertility or infertility, which profoundly affect the quality life in
women (1–3). The prevalence of the disease is 5–10% in re-
productive age women, increases to 20–30% in women with sub-
fertility, and to 40–60% in women with pain and infertility (1–3).
Endometriosis remains as the single major cause for hysterectomy
in reproductive age women in the United States, with an annual
estimated societal cost of ∼$69.4 billion (3). These significant in-
dividual and public health concerns underscore the importance of
understanding the pathogenesis of endometriosis.
Although endometriosis has been traditionally viewed as an
estrogen (E2)-dependent and progesterone (P4)-resistant disease
(1–3), its pathogenesis remains an enigma in reproductive medi-
cine. The most widely accepted hypothesis first advanced by
Sampson in 1927 is that viable endometrial tissue fragments move
in a retrograde fashion through the fallopian tubes into the pelvic
cavity during menstruation (4). These ectopic endometrial cells
invade the underlying peritoneum, survive for considerable time
(∼7–8 y), and establish peritoneal endometriosis characterized by
heterogeneous lesions/phenotypes.
Current treatment strategies include surgical intervention,
medical therapy, or a combination of both. After surgical removal
of endometriosis lesions, the disease reestablishes within 3–5 y in
∼30–50% of women. Surprisingly, the disease reoccurs in ∼10% of
women who have had the uterus and both ovaries removed (5).
Hormonal therapy to induce a hypoestrogenic state through the
use of oral contraceptives, progestagens, androgenic agents, and
gonadotropin releasing hormone analogs can be prescribed only
for a short time due to undesirable side-effects, pseudomeno-
pause, and bone density loss in reproductive age women (1–3, 5).
Nevertheless, the recurrence rate is ∼50–60% after cessation of
therapy within a year (5). Together, existing treatment modalities
fail to prevent recurrence of disease, and affect pregnancy and
reproductive health of women. There is a fundamental need to
identify potential cell signaling pathways for nonestrogen or
nonsteroidal targets for endometriosis.
Peritoneal fluid concentrations of prostaglandin E2 (PGE2) are
higher in women with endometriosis, and this increased PGE2 plays
an important role in survival and growth of endometriosis lesions
(6–9). Inhibition of PGE2 biosynthesis impedes growth of endo-
metriosis (9) and chronic pelvic pain in women (7), and decreases
growth of endometriosis lesions in animal models (8). COX-2 is the
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rate limiting enzyme that regulates biosynthesis of PGE2. The bi-
ological actions of PGE2 are mediated via G protein receptors EP1,
EP2, EP3, and EP4 by integrating multiple cell signaling pathways
(10). Recent studies from our laboratory indicate that selective
inhibition of EP2 and EP4 inhibits adhesion, invasion, growth, and
survival of human endometriotic epithelial and stromal cells by
modulating integrins, matrix metalloproteinases (MMPs) and tissue
inhibitors of metalloproteinases (TIMPs), cell cycle, survival, and
apoptosis pathways in vitro (11–14).
The objectives of the present study were to determine the phar-
macological effects of selective inhibition of EP2/EP4 on: (i) growth
and survival of endometriosis lesions; (ii) molecular and cellular
aspects of the pathogenesis of endometriosis; (iii) pelvic pain and
molecular pain pathways; and (iv) endocrine and immune modula-
tion in the endometrium, using chimeric mouse model of endome-
triosis as preclinical testing platform. Our novel results collectively
indicate that inhibition of PGE2-EP2/EP4 signaling could emerge as
a potential nonestrogen or nonsteroidal therapy for endometriosis.
Results
Therapeutic Effects of Selective Inhibition of EP2/EP4 on Growth of
Endometriosis Lesions. Xenograft of mixed populations of endo-
metriotic epithelial cells 12Z-GFP and stromal cells 22B-RFP in
ovariectomized and estrogen-treated nude mice induced peritoneal
endometriosis characterized by heterogeneous white and bleeding
red lesional phenotypes which is similar to the human peritoneal
endometriosis (Fig. 1). Histomorphology of the endometriosis le-
sions showed that epithelial cells 12Z-GFP formed endometrial
glands and stromal cells 22B-RFP formed stroma and thus estab-
lished functional communicating endometrial glands and sur-
rounding stroma similar to the human peritoneal endometriosis.
Under gross examination, 8–10 endometriosis lesions/mouse were
visible. Importantly, under fluorescence dissection microscopy, 20–
25 clusters of endometriosis lesions/mouse were detectable. Among
the visible peritoneal endometriosis lesions, ∼60% were white le-
sions and 40% were bleeding red lesions (Fig. 1 A–D). Selective
inhibition of EP2/EP4 from days 15–28 of xenograft decreased
(P < 0.05) the growth of endometriosis lesions up to 60% dose-
dependently, and the maximal effect was observed at 25 mg/kg.
Inhibition of EP2/EP4 decreased (P < 0.05) the growth of epithelial
cells 12Z-GFP and stromal cells 22B-RFP up to 70% and 60%
respectively (Fig. 1 E–J). Real-time in vivo bioimaging, fluorescence
dissection microscopy imaging, and morphometry data together
indicated that pharmacological inhibition of EP2/EP4 decreased
(P < 0.05) growth (size and volume) of endometriosis lesions. In
addition, EP2-I/EP4-I (25 mg/kg) did not affect functions of liver
and kidney (Fig. 1K), and the treated mice were apparently healthy.
Inhibition of EP2/EP4-Induced Apoptosis of Endometriosis Lesions.
Inhibition of EP2/EP4 increased (P < 0.05) TUNEL positive ep-
ithelial as well as stromal cells in endometriosis lesions (Fig. 2 A1–
A3). Next, we determined epithelial-stromal cell specific apopto-
sis. Inhibition of EP2/EP4 induced (P < 0.05) expression of
cl-caspase-3 (Fig. 2 B1–B5) and cl-PARP (Fig. 2 C1–C5) proteins in
both epithelial and stromal cells of endometriosis lesions. We
examined eight lesions per mouse, among them ∼60% lesions
showed increased expression of cl-caspase-3 and cl-PARP proteins
and increased TUNEL-positive cells. These lesions were classified
as regressing lesions and selected for further study to investigate
the underlying molecular pathways through which inhibition of
EP2/EP4 induced apoptosis of endometriosis lesions.
Inhibition of EP2/EP4 Decreased Survival, Invasion, and Proinflammation
Machinery Proteins in Endometriosis Lesions. Inhibition of EP2/EP4
decreased (P < 0.05) expression of PGE2 biosynthesis and signaling
proteins COX-2, and EP2 and EP4 respectively (Fig. 3 A1–C3);
proinflammatory cytokine proteins IL1β, TNFα, and IL6 (Fig. 3
D1–F3); important intracellular survival pathway proteins p-AKT,
p-ERK1/2, and active β-catenin (Fig. 3 G1–I3); and invasion
pathway proteins MMP2 and MMP9 (Fig. 3 J1–K3) in an epi-
thelial-stromal cell specific as well as protein-specific pattern in
endometriosis lesions.
Inhibition of EP2/EP4 Decreased Estrogen Biosynthesis and Signaling and
Increased Progesterone Signaling Machinery Proteins in Endometriosis
Lesions. Cytochrome p450 aromatase, ERα, and ERβ proteins were
abundantly expressed in epithelial and stromal cells of endometri-
osis lesions. Inhibition of EP2/EP4 decreased (P < 0.05) p450 aro-
matase, ERα, and ERβ proteins (Fig. 3 L1–N3) in both cell types of
endometriosis lesions. Interestingly, PR protein was not expressed
in epithelial cells and expressed at very low levels in the stromal
cells, which supports the typical P4-resistance state of endometriosis.
Inhibition of EP2/EP4 increased (P < 0.05) expression of PR both
in epithelial and stromal cells of endometriosis lesions and restored
P4-responsive state (Fig. 3 O1–O3). Surprisingly, expression of one
of the important transcription factors SF1 in epithelial and stromal
cells of endometriosis lesions was not modulated by EP2/EP4 in-
hibition (Fig. 3 P1–P3), suggesting posttranslational mechanisms.
Inhibition of EP2/EP4 Decreased Angiogenesis of Endometriosis Lesions.
The primary angiogenesis signal vascular endothelial growth factor
(VEGF) was highly expressed in the stromal cells but not in
Fig. 1. Effects of inhibition of EP2 and EP4 (EP2/4-I) on growth and survival of endometriosis lesions. Fluorescence microscopy of (A1) human endometriotic epithelial
cells 12Z-GFP and (A2) stromal cells 22B-RFP grown in coculture and imagedwith red or green channels and (A3) overlay of both channels. (B) Amixture of epithelial cells
12Z-GFP and stromal cells 22B-RFP suspension was injected into the peritoneal cavity of nude mice, peritoneal endometriosis was induced (day 1), and necropsied on day
29 as detailed inMaterials andMethods. Gross examination of white (1) and bleeding red (2) endometriosis lesions phenotypes with adhesions (ad). (C1–C3) Fluorescence
zoomstereo microscopy examination of dissemination of 12Z-GFP and 22B-RFP cells of endometriosis lesions in the peritoneal cavity. Histomorphology of endometriosis
lesions, (D1) 12Z-GFP cells formed the glands (GLE), (D2) 22B-RFP formed the stroma (STR), and (D3) established communicating glands and stroma. (E) Endometriosis
nude mice were treated with EP2 (AH6809) and EP4 (AH23848) inhibitors (EP2/4-I) at 5, 10, or 25 mg/kg, i.p, at 24h intervals from days 15–28 of xenograft. Growth of
endometriosis lesions was imaged in vivo real-time on days 1 (before), 7, 14, 21, and 28 of xenograft. Representative in vivo images for (F) control and (G) EP2/4-I at
25 mg/kg on day 28 are shown. (H) Gross number and volume of endometriosis lesions. (I) Fluorescence zoomstereo microscopy examination of peritoneal
endometriosis lesions and (J) quantity of 12Z-GFP and 22B-RFP cells in these lesions. (K) Plasma biochemical parameters. *Control vs. EP2/4-I, P < 0.05, n = 6.











epithelial cells of endometriosis lesions. Inhibition of EP2/EP4
decreased (P < 0.05) expression of VEGF protein (Fig. 3 Q1–Q3)
in stromal cells. Expression pattern of the endothelial cell marker
protein Von Willebrand factor (vWF) indicated the density of
endothelial cells around the endometriosis lesions. Inhibition of
EP2/EP4 decreased (P < 0.05) expression of vWF, and in turn,
decreased existing and newly developing angiogenesis network of
endometriosis lesions (Fig. 3 R1–R3).
Inhibition of EP2/EP4 Decreased Pelvic Pain in Endometriosis.We used
chimeric Rag2g(c) intact mouse model of endometriosis to
investigate pain mechanisms. Xenograft 12Z-GFP and 22B-RFP
cells induced peritoneal endometriosis characterized by hetero-
geneous white and red lesional phenotypes similar to that of nude
mouse model as shown (Fig. 1 B and I). Vaginal cytology con-
firmed that peritoneal endometriosis progressively prolonged the
E2 phase of the estrous cycle after 3 wk of disease, suggesting
a compromised estrous cycle. Inhibition of EP2/EP4 decreased
(P < 0.05) the growth of endometriosis up to 60% (Fig. 4A) irre-
spective of E2 or P4 phase of the estrous cycle. Importantly, in-
hibition of EP2/EP4 decreased growth, survival, and dissemination
of endometriosis lesions in such an E2-dominant state. As shown in
Fig. 3 above, the epithelial cells 12Z and stromal cells 22B of en-
dometriosis lesions have inherent capacity to produce E2. There-
fore, the source of E2-dominance appears to be the peritoneal
endometriosis lesions rather than mouse ovaries in this model.
Mechanical hyperalgesia was assessed by stimulating the pelvic
floor with von-Frey filaments and the threshold force required to
elicit a behavioral withdrawal response was determined. Perito-
neal endometriosis decreased (P < 0.05) pelvic floor withdrawal
threshold (reflecting increased pain to von-Frey stimulus). In-
hibition of EP2/EP4 increased (P < 0.05) pelvic floor pain
threshold or decreased mechanical hyperalgesia irrespective of E2
versus P4 phase of the estrous cycle (Fig. 4B, data from E2 phase
is shown). Interestingly, the observed pelvic floor mechanical
hyperalgesia is correlated with growth of endometriosis lesions.
We examined innervation (formation of new nerve fibers) of
endometriosis lesions by determining the expression of PGP9.5
(pan neuronal marker), TRPV1 (afferent nerve marker), CGRP
(C-sensory nerve fiber marker), SP (Aδ-sensory nerve fiber marker),
and VMAT (sympathetic nerve fiber marker) proteins around the
Fig. 2. Effects of inhibition of EP2 and EP4 (EP2/4-I) on induction of apo-
ptosis and activation of caspase-3 and PARP proteins in endometriosis le-
sions. (A) TUNNEL assay. (B) The 22B-RFP stromal cells (STR) were labeled
with Alexa 594 (red) and cl-caspase3 protein was labeled with Alexa 488
(green) antibodies. (C) The 12Z-GFP epithelial cells (GLE) were labeled with
Alexa 488 (green), and cl-PARP protein was labeled with Alexa 594 (red)
antibodies. Nuclei were stained with DAPI (blue). (D) IgG controls. Peritoneal
endometriosis was induced in nude mice, treated with EP2 (AH6809) and EP4
(AH23848) inhibitors (EP2/4-I) at 25 mg/kg body weight, and necropsied as
detailed in Fig. 1. *Control vs. EP2/4-I, P < 0.05, n = 8.
Fig. 3. Effects of inhibition of EP2 and EP4 (EP2/4-I) on regulation of key proteins involved in inflammation, survival, invasion, angiogenesis, and biosynthesis
and signaling of PGE2, E2, and P4 in endometriosis lesions. (A1–A3) COX-2. (B1–B3) EP2. (C1–C3) EP4. (D1–D3) IL1β. (E1–E3) TNFα. (F1–F3) IL6. (G1–G3) p-AKT.
(H1–H3) p-ERK1/2. (I1–I3) β-catenin. (J1–J3) MMP2. (K1–K3) MMP9. (L1–L3) p450 aromatase. (M1–M3) ERα. (N1–N3) ERβ. (O1–O3) PR. (P1–P3) SF-1. (Q1–Q3)
VEGF. (R1–R3) vWF proteins. (S1–S2) IgG controls. Nuclei were stained with DAPI (blue), and each protein was stained using Alexa 488 (green) or Alexa 594
(red) secondary antibodies. Peritoneal endometriosis was induced in nude mice, treated with EP2 (AH6809) and EP4 (AH23848) inhibitors (EP2/4-I) at 25 mg/kg,
and necropsied as detailed in Fig. 1. *Control vs. EP2/4-I, P < 0.05, n = 8.
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endometriosis lesions during E2 phase of the estrous cycle. Results
(Fig. 4C) indicated that endometriosis lesions developed their
own innervations (PGP9.5-positive neurites), which include sensory/
afferent nerve fibers (CGRP-, SP-, TRPV1-positive neurites) and
sympathetic/efferent nerve fibers (VMAT-positive neurites). In-
hibition of EP2/EP4 decreased (P < 0.05) the expression of PGP9.5,
TRPV1, CGRP, SP, and VMAT proteins and in turn decreased C
and Aδ sensory fiber innervation of endometriosis.
Visceral primary afferent neurons (nociceptors) detect and
transmit information from the pelvic region into the spinal cord.
The cell bodies of these primary afferent neurons are located in
the lumbosacral dorsal root ganglia (DRG). Inflammation con-
tributes to the sensitization of the primary afferent neurons
leading to the enhancement of visceral sensitivity to mechanical
stimulation. Pelvic organs are primarily innervated from L1, L2,
L3, L4, L5, and S1 of the spinal cord. Therefore, we next exam-
ined regulation of proinflammatory molecular markers in the
DRG neurons from L1 to S1. Results indicated that PGE2 bio-
synthetic and signaling machinery proteins COX-2, EP2 and EP4
(Fig. 4 D–F) and proinflammatory cytokine proteins IL1β, TNFα,
and IL6 (Fig. 4 G–I) were abundantly expressed in L1, L2, L3, L4,
L5, and S1 DRG neurons. Importantly, inhibition of EP2/EP4
decreased (P < 0.05) expression of these proteins in DRG neurons
L1-S1 selectively at different levels.
Inhibition of EP2/EP4 Decreased E2-Dominance and P4-Resistance in
Eutopic Endometrium in Endometriosis. We used chimeric Rag2g(c)
intact mouse model of endometriosis to investigate endocrine-
Fig. 4. Effects of inhibition of EP2 and EP4 (EP2/4-I) on innervation of endometriosis lesions, regulation of proinflammatory machinery proteins in DRG, and noci-
ception of pelvic pain in endometriosis. (A) Growth of endometriosis lesions measured by gross examination andmorphometry (A and B) and fluorescence zoomstereo
microscopy (C and D). (B) Pelvic floor referred hyperalgesia using von-Frey test. (C) Expression of neuronal markers PGP9.5, CGRP, SP, TRPV1, and VMAT proteins in
endometriosis lesions. Expression of COX-2 (D), EP2 (E), EP4 (F), ILβ (G), TNFα (H), and IL6 (I) proteins in DRG neurons L1, L2, L3, L4, L5, and S1. (J) IgG controls. GLE,
glandular epithelium; STR, stromal cells. Nuclei stained with DAPI (blue), each protein stained with Alexa 488 (green) or Alexa 594 (red) secondary antibodies. *Control
vs. EP2/4-I, P < 0.05, n = 8. After 3 wk of disease, endometriosis Rag2g(c) mice were treated with EP2 (AH6809) and EP4 (AH23848) inhibitors (EP2/4-I) at 25 mg/kg for
2 wk. At the end of 5 wk, the mice were necropsied at the E2 versus P4 phase of the estrous cycle as confirmed by vaginal cytology, and data from E2 phase shown.











immune modulations in the eutopic endometrium. Inhibition of
EP2/EP4 decreased (P < 0.05) the expression of PGE2 biosynthetic
and signaling proteins COX-2, EP2, and EP4 (Fig. 5 A1–C3) and
proinflammatory cytokine proteins IL1β, TNFα, and IL6 (Fig. 5
D1–F3) proteins in epithelial and stromal cells of endometrium.
The key E2 biosynthesis enzyme p450 aromatase protein was only
expressed in stromal cells but not in the epithelial cells of endo-
metrium. Interestingly, inhibition of EP2/EP4 decreased (P < 0.05)
expression of p450 aromatase protein (Fig. 5 G1–G3) in stromal
cells and concomitantly increased its expression in epithelial cells of
endometrium. ERα protein (Fig. 5 H1–H3) was expressed in both
epithelial and stromal cells, and inhibition of EP2 and EP4 de-
creased (P < 0.05) its expression in both cell types of endometrium.
ERβ protein (Fig. 5 I1–I3) predominantly expressed in epithelial
cells compared with stromal cells, and inhibition of EP2 and EP4
decreased (P < 0.05) its expression in both cell types of endome-
trium. PR protein (Fig. 5 J1–J3) was not expressed in stromal cells
but was expressed in glandular epithelial cells. Importantly, in-
hibition of EP2/EP4 increased/restored (P < 0.05) its expression
in stromal cells and concomitantly decreased its expression in
glandular epithelial cells of endometrium.
Discussion
PGE2 plays an important role in the pathogenesis of endome-
triosis (6–9). COX-2, EP2, EP4, p-ERK1/2, p-AKT, β-catenin,
MMP2, and MMP9 proteins are highly expressed/activated in
endometriosis lesions in women (11–15). PGE2 increases SF1,
StAR, and p450 aromatase genes and stimulates de novo bio-
synthesis of E2 which in turn increases PGE2 biosynthesis in
endometriosis lesions (1). PGE2 and E2 (ERα and ERβ) in-
teractive pathways appear to suppress PR expression leading to
loss of P4 action and P4-resistance in endometriosis lesions (1,
16). In addition, endometriosis lesions secrete proinflammatory
cytokines (17). COX-2/PGE2 induces VEGF and promotes an-
giogenesis of endometriosis lesions (8).
Results of the present study indicate that inhibition of EP2/
EP4 suppresses survival, invasion, biosynthesis, and signaling of
PGE2 and E2, production of proinflammatory cytokines, and
increases P4 signaling machinery proteins in an epithelial and
stromal cell-specific pattern in endometriosis lesions. These re-
sults together establish that inhibition of EP2/EP4 restores appro-
priate cross-talk among PGE2, E2, and P4 pathways and converts
the proinflammatory, E2-dominant, and P4-resistant state into a P4-
responsive state and thus decreases growth, survival, and dissemi-
nation of peritoneal endometriosis lesions. An inverse relationship
among EP2, EP4, p450 aromatase, ERα, ERβ, and PR proteins in
epithelial and stromal cells suggests that PGE2 and E2 interactive
pathways are the important regulators of PR signaling in endo-
metriosis lesions. However, the underlying molecular interactive
mechanisms among EP2/EP4, ER, and PR in endometriosis lesions
in an epithelial-stromal cell specific pattern are largely unknown.
The mechanisms underlying the detection and transmission of
nociceptive signals from endometriosis lesions are also largely
unknown. i.p. concentrations of PGE2 (18), IL1β, and TNFα (19)
are higher in women with endometriosis. PGE2 acts on the pe-
ripheral nociceptors and increases responsiveness to peripheral
stimuli through TRPV1 and induces chronic inflammatory pain
through EP2 and EP4 (20, 21). Localized peripheral inflammation
increases expression of COX-2 protein in the spinal cord (22) and
DRG neurons (23) and EP4 protein in L5 DRG neurons (20, 21).
Pharmacological and genomic inhibition of COX-2 (22) or EP4
(20, 21) decreases inflammatory pain hypersensitivity. Further-
more, activation of EP2 or EP4 increases TRPV1 activity in DRG
neurons (20, 21). Inhibition of EP4 decreases PGE2-induced
sensitization of DRG neurons and release of neuropeptides SP
and CGRP (20, 21). Advanced active endometriosis lesions are
innervated by sympathetic and sensory C and Aδ fibers and they
express CGRP and TRPV1 proteins in a rat allograft model (24).
Results of the present study indicate that endometriosis lesions
induce innervation of C and Aδ afferent sensory and efferent
nerve fibers around the endometriosis lesions, promote proin-
flammatory microenvironment of DRG neurons from L1-S1
which innervate pelvis and pelvic organs, and increase pelvic floor
hyperalgesia. Inhibition of EP2/EP4 decreases innervation of en-
dometriosis lesions, decreases the proinflammatory state of DRG
neurons, and suppresses peripheral nociception. These results
together establish that the inflammatory response of endometri-
osis lesions initiates a cascade of events resulting in enhancement
of the responsiveness of nociceptors and DRG neurons, and in-
hibition of EP2/EP4 suppresses these pain pathways and decreases
endometriosis-induced pelvic pain. In women with endometriosis,
the pelvic pain can be assessed by bilateral hyperalgesia and
allodynia from T9-S1 spinal segments (25) and mechanical
hyperalgesia of the pelvis, where pain is reported in response to
applied pressure. Although the von-Frey DRG mice models are
widely used to measure hyperalgesia in pain models, we used this
interactive approach, to our knowledge for the first time, to
measure the pelvic floor pain threshold in endometriosis chimeric
mouse model with translational relevance.
The underlying causes of endometriosis-induced infertility re-
main unclear and are likely multifactorial. In women with endo-
metriosis, the microenvironment of the endometrium becomes
proinflammatory, E2-dominant, and P4-resistant, and thereby im-
pairs receptivity for establishment of pregnancy (1, 2, 26, 27). The
endometrium first becomes hyperresponsive to E2 and then re-
sistant to P4 (1, 16, 28). The loss of normal endometrial function
becomes more evident with progression of disease (28). The dis-
ruption of these signaling processes in endometrial epithelial and
stromal cells appears to be a consequence of growth of peritoneal
Fig. 5. Effects of inhibition of EP2 and EP4 (EP2/4-I) on regulation of key proteins involved in biosynthesis and signaling of PGE2, E2, and P4, and proinflammation
in eutopic endometrium in endometriosis. (A1–A3) COX-2. (B1–B3) EP2. (C1–C3) EP4. (D1–D3) ILβ. (E1–E3) TNFα. (F1–F3) IL6. (G1–G3) p450 aromatase (p450arom).
(H1–H3) ERα. (I1–I3) ERβ. (J1–J2) PR protein. (K1–K2) IgG controls. Nuclei were stained with DAPI (blue), each protein was stained with Alexa 488 (green) secondary
antibody. GLE, glandular epithelium; LE, luminal epithelium; STR, stromal cells. *Control vs. EP2/4-I, P < 0.05, n = 8. Peritoneal endometriosis was induced in Rag2g
(c) mice, treated with EP2 (AH6809) and EP4 (AH23848) inhibitors (EP2/4-I) at 25 mg/kg, necropsied as detailed in Fig. 4, and data from E2 phase shown.
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endometriosis lesions, which might be orchestrated by progressive
deregulated interactions among PGE2, E2, and P4.
Results of the present study indicate that inhibition of EP2/
EP4 decreases PGE2, E2 biosynthesis and signaling, proin-
flammatory cytokine production, and increases P4 signaling
machinery proteins in an epithelial-stromal cell-specific pattern
in the eutopic endometrium. These results together demonstrate
that inhibition of EP2/EP4 suppresses E2-dominant state and
concomitantly increases P4-responsive state of the endometrium.
Thus, it restores the ability of the endometrium respond appro-
priately to PGE2, E2, and P4 and its functional receptivity for es-
tablishment of pregnancy. Specific inverse regulatory relationship
among COX-2, EP2/EP4, p450 aromatase, ERα, ERβ, and PR in
epithelial and stromal cells of the endometrium suggest that
PGE2-E2 interactive pathways are the important regulators of PR
and p450 aromatase. However, the underlying molecular and
cellular mechanisms that lead to restoration of PR and suppres-
sion of ER expression in an epithelial-stromal cell specific pattern
are largely unknown.
In conclusion, results of the present study, to our knowledge for
the first time, indicate that selective pharmacological inhibition of
EP2/EP4: (i) suppresses the growth and survival of endometriosis
lesions; (ii) decreases endometriosis-induced innervation and pelvic
pain; (iii) decreases proinflammatory, E2-dominant, and P4-re-
sistant molecular environment of the endometrium and endome-
triosis lesions; and (iv) restores endometrial functional receptivity
through multiple mechanisms (Fig. S1). Our novel results provide
molecular and preclinical basis to formulate personalized pheno-
type-based long-term nonestrogen or nonsteroidal therapy through
inhibition of EP2/EP4 as a more effective alternative treatment to
existing hormonal therapies for endometriosis. At present, no
therapeutic agents are available to inhibit EP2/EP4 receptors for
the treatment of endometriosis or other inflammatory diseases in
human medicine. Discovery of specific targeted drugs, injectable
antibodies or small molecules to inhibit EP2/EP4 is expected to
provide new clinical trials and open new area of research in en-
dometriosis. Findings of the present study provide new knowledge
that fills an important gap in the current understanding of the
pathogenesis, diagnosis, and treatment of endometriosis.
Materials and Methods
Human fluorescent endometriotic epithelial cell line 12Z and stromal cell line
22B were xenografted and peritoneal endometriosis was induced in immu-
nocompromised mice. The experimental mice were treated with EP2 and EP4
inhibitors. Effects of treatment on growth, survival, pain, and infertility and
the underlying molecular mechanisms were determined (29–37). All pro-
cedures were approved by the Institutional Animal Care and Use Committee
at Texas A&M University. Detail methods (Fig. S2 and Table S1) are provided
in the SI Materials and Methods.
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